

Revolutionizing Autoimmune Disease Management: A Look into the Growing Therapeutics Market

PORTLAND, ID, UNITED STATES, September 15, 2025 /EINPresswire.com/ -- Autoimmune diseases occur when the body's immune system attacks its own healthy tissues, leading to chronic inflammation and damage to various organs. The [autoimmune disease therapeutics market](#) refers to the various medications and treatments used to manage these conditions.

These treatments can include immunosuppressant drugs, biologic therapies, and corticosteroids, among others. They aim to suppress the immune system's abnormal response and reduce inflammation and damage to affected tissues and organs.

The autoimmune disease therapeutics market is a growing industry due to the increasing prevalence of autoimmune diseases worldwide. It includes various pharmaceutical companies and research institutions developing and testing new treatments to improve the management and outcomes of autoimmune diseases.

The report provides an extensive analysis of key winning strategies, changing market dynamics, market size & projections, and competitive landscape. According to the report, the global autoimmune disease therapeutics market is projected to reach \$1.2 billion by 2030, growing at a CAGR of 10.5% from 2025 to 2030. The market is driven by the increasing prevalence of autoimmune diseases, rising R&D investments, and the development of novel therapies.

For more information, visit the report page:

<https://www.alliedmarketresearch.com/request-sample/5185>

The report also provides a detailed analysis of the competitive landscape, highlighting the key players in the market. The major players include AbbVie Inc., Amgen Inc., Bristol Myers Squibb Co., Johnson & Johnson, Eli Lilly and Company, Pfizer Inc., and Novartis International AG.

AbbVie Inc.

Amgen Inc.

Bristol Myers Squibb Co.

Johnson & Johnson

Eli Lilly and Company

Pfizer Inc.

Novartis International AG

Roche Holding AG
Sanofi SA
Merck & Co., Inc.

On the basis of indication, the market is bifurcated into rheumatic disease, type 1 diabetes, multiple sclerosis, inflammatory bowel disease, and others. The rheumatic disease segment held about half of the total market share in 2017 and is expected to maintain its dominance throughout the study period. Moreover, the segment is estimated to manifest the fastest CAGR of 5.2% during the study period, owing to prevalence, surge in R&D activities, and availability of advanced therapeutics.

For more information, please visit: <https://www.alliedmarketresearch.com/purchase-enquiry/5185>

Increasing prevalence of autoimmune diseases: Autoimmune diseases are becoming more prevalent worldwide, which is driving the demand for new and improved treatments.

Technological advancements in drug discovery: Advances in technology are allowing researchers to develop more targeted and effective treatments for autoimmune diseases.

Growing awareness and diagnosis of autoimmune diseases: Improved awareness and diagnostic tools are leading to earlier detection of autoimmune diseases, increasing the demand for effective treatments.

Favorable government initiatives: Government initiatives to support research and development of autoimmune disease treatments, and funding for clinical trials, can help accelerate the development of new therapies.

High cost of treatment: Many autoimmune disease treatments can be expensive, which can limit access to care for some patients and impact market growth.

Patent expiration: The expiration of patents on some of the key drugs used in autoimmune disease treatment can lead to increased competition and a decline in revenue for some pharmaceutical companies.

Overall, the autoimmune disease therapeutics market is driven by the increasing prevalence of autoimmune diseases, technological advancements, and favorable government initiatives, but it can be impacted by cost and patent expiration.

For more information, please visit: <https://www.alliedmarketresearch.com/request-for-customization/5185>

Autoimmune diseases are a group of conditions in which the immune system mistakenly attacks the body's own tissues. This can lead to a wide range of symptoms and complications. The market for autoimmune disease treatments is growing, driven by the increasing prevalence of these conditions and the development of new therapies. The market can be segmented based on the type of autoimmune disease being treated, the type of treatment, and the route of administration.

Type of autoimmune disease: Autoimmune diseases can affect various organs and systems in the body, including rheumatoid arthritis, multiple sclerosis, psoriasis, systemic lupus erythematosus, Crohn's disease, and others. The market can be segmented based on the specific autoimmune disease being treated.

Type of treatment: There are various types of treatments available for autoimmune diseases, including immunosuppressants, biologics, corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), and others. The market can be segmented based on the type of treatment being used.

Route of administration: Autoimmune disease therapeutics can be administered through various routes, including oral, intravenous, subcutaneous, and others. The market can be segmented based on the route of administration of the treatment.

Segmentation helps companies to understand the specific needs of patients, design targeted therapies, and improve the overall effectiveness of treatment options.

Autoimmune disease therapeutics market segmentation

Bispecific Antibody Market <https://www.alliedmarketresearch.com/bispecific-antibody-market-A129947>

Proteomics Market <https://www.alliedmarketresearch.com/proteomics-market>

Analgesics Market <https://www.alliedmarketresearch.com/analgesics-market>

Autoimmune disease therapeutics market segmentation

Allied Market Research (AMR) is a full-service market research and business consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

David Correa
Allied Market Research
+ +1 800-792-5285

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[YouTube](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/849221564>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.